Document is current
Any future updates will be listed below
-
Authors
Park, Jeong A.
Cheung, Nai-Kong V. http://orcid.org/0000-0001-6323-5171
-
Funding
Funding for this research was provided by:
Enid A. Haupt Endowed Chair
The Robert Steel Foundation
Kids Walk for Kids with Cancer
Y-mAbs Therapeutics
NCI Cancer Center Support Grant (P30 CA008748)
Division of Cancer Epidemiology and Genetics, National Cancer Institute (P30 CA008748)
Robert Steel Foundation
- License Information
-
More Information
Article History
Received: 30 October 2020
Accepted: 25 November 2020
First Online: 10 December 2020
Ethics approval and consent to participate
: All animal experiments were approved by the Memorial Sloan Kettering’s Institutional Animal Care and Use Committee (IACUC) and were executed according to the ACUC guidelines. Patient-derived tumor xenografts were established with MSKCC IRB approval.
: Not applicable.
: NKC reports receiving commercial research grants from Y-mabs Therapeutics and Abpro-Labs Inc.; holding ownership interest/equity in Y-Mabs Therapeutics Inc., holding ownership interest/equity in Abpro-Labs, and owning stock options in Eureka Therapeutics. NKC is the inventor and owner of issued patents licensed by MSK to Ymabs Therapeutics, Biotec Pharmacon, and Abpro-labs. Hu3F8 and 8H9 were licensed by MSK to Y-mabs Therapeutics. Both MSK and NKC have financial interest in Y-mabs. NKC is an advisory board member for Abpro-Labs and Eureka Therapeutics. JP has no disclosures to report.
